Top Markets
Coin of the day
Acticor Biotech SAS Acticor Biotech SAS

Acticor Biotech SAS

ALACT
Hisse Senetlerindeki Sıralama #37014
Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating... Acticor Biotech SAS is a clinical-stage biotechnology firm focused on creating therapies for the acute phase of thrombotic conditions. The company's lead compound, glenzocimab, is a humanized monoclonal antibody fragment specifically designed to target a particular platelet glycoprotein. Currently, Acticor Biotech is advancing two clinical programs, both in Phase II/III, for the registration of treatments for ischemic stroke. Additionally, it is conducting two other Phase II trials concerning significant cardiovascular emergencies, with anticipated clinical data expected from both its ischemic stroke research and studies related to COVID-19 respiratory distress syndrome. Established in 2013, the company operates from its headquarters in Paris, France.
Hisse Fiyatı
$0.25974701
Son senkronizasyon: 2025-01-06
Piyasa Değeri
$2.04M
Değişim (1 gün)
0.74%
Değişim (1 yıl)
0.00%
Ülke
FR
Ticaret Acticor Biotech SAS (ALACT)

Kategori

Acticor Biotech SAS (ALACT) için kazanç
Jun 2024 itibarıyla kazanç TTM: $-12.93M
Acticor Biotech SAS şirketinin en son finansal raporlarına göre, mevcut kazancı $-12.93M'dir. 2022 yılında şirket $-19.33M kazanç elde etti, bu 2021 yılındaki $-16.54M kazanca göre önceki yıla göre azalma. Bu sayfada gösterilen kazanç, faiz ve vergiler öncesi kazançtır; yani EBIT.
Acticor Biotech SAS için kazanç geçmişi 2010 - 2026
Her yılın sonundaki kazanç
Yıl Kazanç Değiştir
2026 (TTM) $-12.93M -43.60%
2023 $-22.92M 18.60%
2022 $-19.33M 16.85%
2021 $-16.54M 50.20%
2020 $-11.01M 86.82%
2019 $-5.89M -14.36%
2018 $-6.88M -41.98%
2017 $-11.86M 2,061.40%
2016 $-548.85K -76.37%
2015 $-2.32M 97.57%
2014 $-1.18M -131.38%
2013 $3.75M -11.81%
2012 $4.25M 30.59%
2011 $3.25M 275.68%
2010 $865.72K 0.00%
Benzer şirketler veya rakipler için kazanç
Şirket Kazanç Kazanç Farkı Ülke
$5.27B -40,906.21%
US
$1.95B -15,190.08%
NL
$-4.02B 30,968.98%
AU
$-3.09B 23,780.79%
US
- -
CH